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Abstract
Background: Prostate cancer recurrence involves increased growth of cancer epithelial cells, as androgen dependent
prostate cancer progresses to castrate resistant prostate cancer (CRPC) following initial therapy. Understanding CRPC
prostate regrowth will provide opportunities for new cancer therapies to treat advanced disease.
Methodology/Principal Findings: Elevated chemokine expression in the prostate stroma of a castrate resistant mouse
model, Tgfbr2
fspKO, prompted us to look at the involvement of bone marrow derived cells (BMDCs) in prostate regrowth. We
identified bone marrow cells recruited to the prostate in GFP-chimeric mice. A dramatic increase in BMDC recruitment for
prostate regrowth occurred three days after exogenous testosterone implantation. Recruitment led to incorporation of
BMDCs within the prostate epithelia. Immunofluorescence staining suggested BMDCs in the prostate coexpressed
androgen receptor; p63, a basal epithelial marker; and cytokeratin 8, a luminal epithelial marker. A subset of the BMDC
population, mesenchymal stem cells (MSCs), were specifically found to be incorporated in the prostate at its greatest time of
remodeling. Rosa26 expressing MSCs injected into GFP mice supported MSC fusion with resident prostate epithelial cells
through co-localization of b-galactosidase and GFP during regrowth. In a human C4-2B xenograft model of CRPC, MSCs
were specifically recruited. Injection of GFP-labeled MSCs supported C4-2B tumor progression by potentiating canonical
Wnt signaling. The use of MSCs as a targeted delivery vector for the exogenously expressed Wnt antagonist, secreted
frizzled related protein-2 (SFRP2), reduced tumor growth, increased apoptosis and potentiated tumor necrosis.
Conclusions/Significance: Mesenchymal stem cells fuse with prostate epithelia during the process of prostate regrowth.
MSCs recruited to the regrowing prostate can be used as a vehicle for transporting genetic information with potential
therapeutic effects on castrate resistant prostate cancer, for instance by antagonizing Wnt signaling through SFRP2.
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Introduction
Prostate cancer mortality continues to rise as the aging
population expands. After surgical intervention, radiation, and
androgen ablation therapy, cancer recurrence is androgen-
independent and is termed castrate resistant prostate cancer
(CRPC). Patients with CRPC are primarily given palliative care
since conventional chemotherapeutics do little to delay mortality
from the disease. Prostate growth and regrowth has been the
subject of stem cell studies, but not with respect to recruited cell
types [1,2]. We used transgenic mouse models to help understand
the involvement of recruited cells in prostate regrowth.
Prostatic epithelial Wnt signaling was identified in transgenic
mouse models of CRPC. One such model we developed had a
conditional stromal knockout of the TGF-b type II receptor,
termed Tgfbr2
fspKO, [3]. FSP1-Cre enabled targeted recombina-
tion in mesenchymal-derived cells, including fibroblasts [3,4]. The
prostatic stroma of Tgfbr2
fspKO mice independently contributed to
transformation of the adjacent epithelia as well as castrate
resistance. The mechanism for the castrate resistant phenotype
was associated with stromal fibroblastic expression of Wnt ligands,
that in turn activated canonical Wnt signaling in the epithelia
[5,6]. Adenoviral transduction of the Wnt signaling antagonist,
secreted frizzled related protein-2 (SFRP2) restored castrate
responsiveness in the Tgfbr2
fspKO mice [5]. However, systemic
SFRP2-adenovirus treatment in Tgfbr2
fspKO mice was associated
with morbidity. Another model with prostatic epithelial expression
of constitutively activated b-catenin developed HGPIN and
sustained growth following castration [7]. Additionally, human
CRPC C4-2B cells reportedly have elevated autocrine Wnt
signaling compared to their androgen dependent parent cell line,
LNCaP [8].
CRPC, tissue remodeling, and cancer progression are generally
associated with the recruitment of bone marrow derived cells
PLoS ONE | www.plosone.org 1 September 2010 | Volume 5 | Issue 9 | e12920[9,10,11]. In a mouse model of damaged liver, during regener-
ation the recruited BMDCs contributed to the new liver epithelia
[12]. Similar BMDC incorporation occurs in gastrointestinal
epithelia associated with elevated proliferation and inflammation
[13,14]. A specialized type of BMDCs, mesenchymal stem cells
(MSCs), are recruited to sites of inflammation and proliferation
including wound healing and cancer [15]. Multipotent MSCs can
differentiate into multiple cell types including osteoblasts, chon-
drocytes, adipocytes, and fibroblasts [16]. In various models of
cancer, MSCs potentiate disease progression. In a model of breast
cancer, MSCs promoted metastasis [17]. In a model of prostate
cancer metastasis, manipulating MSCs to deliver the urokinase-
type plasminogen antagonist amino-terminal fragment by co-
injection with PC3 cells in the bone decreased tumor angiogenesis
and osteolytic activity [18]. MSCs home to tumors as a result of
cytokine and chemokine expression in the tumor microenviron-
ment. The efficacy of MSCs as a therapeutic tool has been tested
through the targeted delivery of exogenously expressed soluble
factors [19,20]. For example, patients with heart damage have
received MSCs that home to damaged and necrotic tissue for
wound repair [21]. We rationalized that MSC therapy may benefit
patients with CRPC in a similar manner.
Weexamined BMDC recruitmenttotheprostateduring regrowth.
Co-expression of prostate markers with BMDCs suggested that these
recruited cells were also incorporated into the prostate epithelia. We
further identified MSCs fusing with prostatic epithelia. Using an
orthotopic C4-2B xenograft model system, we found that recruited
MSCs could further contribute to tumor progression by enhanced
Wnt signaling. The overexpression of SFRP2 by MSCs homed to the
tumors and restored tumor responsiveness to castration.
Results
Previous studies with the Tgfbr2
fspKO mouse model showed that
the conditional stromal knockout of TGF-b signaling led to CRPC
[5]. To fully understand the stromal changes that led to the
development of CRPC, we isolated prostate stromal RNA through
laser capture microdissection for microarray analysis and compared
Tgfbr2
fspKO to control Tgfbr2
FloxE2/FloxE2 mouse stroma. The
microarray data has been deposited in the NCBI Gene Expression
Omnibus (GEO, GSE22130). This revealed the differential
regulation of numerous cytokines and chemokines in Tgfbr2
fspKO
compared to control Tgfbr2
FloxE2/FloxE2 mouse stroma (Table 1).
Microenvironments richinchemokine andcytokinesignaling recruit
many cell types, including BMDCs [22].
BMDCs are recruited to the prostate during cancer develop-
ment. Since BMDCs are also recruited during tissue remodeling,
we wanted to identify their role in prostate regrowth following
castration. Previous studies have described the histologic identi-
fication of macrophage and monocytes recruited in prostate
cancer [11,23]. To better localize BMDCs during prostate
regrowth we generated GFP-bone marrow chimeric wild type
mice, which were either intact or castrated. Prostate regrowth was
monitored at day zero, three, seven, and 28 days following
implantation of exogenous testosterone. Immunohistochemical
GFP localization identified BMDCs recruited to the prostate
during regrowth in response to castration (Figure 1). Intact
prostates had low basal BMDC recruitment (Figure 1A). Castra-
tion induced a slight, but statistically significant increase in
recruitment (Figure 1B). Three and seven days following
testosterone supplementation, prostates reached the highest levels
of recruitment (Figure 1C, D). At 28 days following testosterone
supplementation, when the prostate was fully regrown, the level of
detectible BMDCs had fallen, comparable to basal levels
(Figure 1E–F). Of particular interest was the appearance of
BMDCs residing within the epithelial compartment (Figure 1F).
BMDC recruitment during active prostate remodeling is quanti-
tated in Figure 1G. BMDC incorporation in the epithelial
compartment was observed throughout the duration of recruit-
ment from castration to full regrowth. However, the presence of
BMDCs at four weeks when the prostates had resumed normal
homeostasis suggested that BMDCs directly contributed to the
regenerated prostate tissue.
We characterized the BMDCs that appeared to incorporate into
the prostate epithelia. GFP expression was immunolocalized with
prostate tissue markers (Figure 2). We found that co-expression of
GFP with androgen receptor indicated the prostate cell lineage of
stromal or epithelial cells (Figure 2A). Furthermore, basal and
prostate luminal epithelial cells identified by p63 and cytokeratin
8, respectively, also co-expressed GFP (Figure 2B, C). We also
noted limited co-expression of GFP with CD45, indicating
hematopoietic lineage cells (Figure 2D). These results indicated
that although a large population of BMDCs is recruited to the
prostate, comparatively smaller populations of the total BMDC
population seem to incorporate into the tissue long term.
We hypothesized that at least a subset of the incorporated
BMDCs were mesenchymal stem cells (MSCs) based on evidence
that 1) MSCs are less than one percent of the total bone marrow
Table 1. Selected List of Chemokines.
Primary Sequence Name Average Fold Change
Ccl12 23.5079
Ccl19 2.9717
Ccl5 270.1794
Ccl6 226.8950
Ccl8 239.9607
Ccl9 211.6369
Csf1r 29.6176
Csf2 162.4770
Cx3cl1 225.0406
Cxcl10 225.4580
Cxcl12 77.3219
Cxcl13 247.1429
Cxcl16 220.5419
Cxcl9 249.5591
Epo 40.0280
Ifna12 38.8468
Ifnz 159.8488
Il18 22.1320
Il18bp 213.0765
Il1f8 3.3513
Il28 10.2366
Il4 23.7385
Il6st 231.2994
Selected chemokines altered in Tgfbr2
fspKO mouse stroma compared to
Tgfbr2
FloxE2/FloxE2 mouse stroma. Negative values indicate the chemokine was
downregulated in the Tgfbr2
FloxE2/FloxE2 stroma and upregulated in the
Tgfbr2
fspKO stroma. Positive values indicated the chemokine was upregulated in
the Tgfbr2
FloxE2/FloxE2 stroma and downregulated in the Tgfbr2
fspKO stroma.
Values are averaged from three independent data sets. Each value had .2-fold
difference and a p-value ,0.01.
doi:10.1371/journal.pone.0012920.t001
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tissue remodeling, and 3) MSCs are known to incorporate into
regenerated tissues [12,24]. We next determined the recruitment
of MSCs to the prostate during regrowth. We generated primary
cultured MSCs from adult chicken b-actin-GFP mouse bone
marrow [25]. The MSC trilineage differentiation potential was
Figure 1. BMDCs were recruited to the prostate during regrowth. GFP-BMDC (brown) recruitment was localized in prostates of GFP chimeric mice.
BMDCs were quantitated in prostates of A) intact mice, B) two months post-castration, C) castrated mice supplemented with exogenous testosterone for
three days, D) castrated mice supplemented with exogenous testosterone for seven days, and E) castrated mice supplemented with exogenous testosterone
for 28 days. F) Higher magnification of castrated prostates supplemented with exogenous testosterone for 28 days indicated BMDC recruitment to the
epithelial ductal compartment. Scale bar indicates 50 mm for panels A–E and 25 mm for panel F. G) The bar graph quantifies the percentage of GFP-positive
BMDCs recruited to the prostate at the indicated time points during regrowth. Oneway ANOVA was performed to test differences between the experimental
and control groups (n=3 per group), followed by Dunnett’s post-hoc tests. Statistically significant values are indicated with * in the bar graph. Error bars
indicate standard deviation. The omnibus of F statistic from the ANOVA was 43.3 with 4 and 10 degrees of freedom (p,0.0001). Dunnett’s post-hoc tests
showed differences between intact (mean =0.0227) and castrated (cast) (mean =0.0615) (p,0.0003), cast +3dT (mean =0.00936) (p,0.0001), and cast +7dT
(mean =0.0750) (P,0.0001). The intact group did not differ from cast +28dT (mean =0.0360) (p,0.1629).
doi:10.1371/journal.pone.0012920.g001
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indicated with oil red-O staining, chondrocytes indicated with
alcian blue staining, and osteocytes indicated by alkaline
phosphatase staining (Figure 3). The multipotential MSCs were
tested for the expression of known chemokine receptors. As
expected, the MSCs expressed CCR5, CCR2, and CXCR4. Next,
we measured the expression of corresponding chemokines in
prostates during regrowth, to determine a mechanism for MSC
homing. We isolated RNA from castrated prostates and castrated
prostates given testosterone for three days. CCL5 was confirmed
to be elevated 2.6-fold during prostate regrowth (Student’s t-test,
p=0.0224) compared to castrated controls. However, CCL2 and
SDF-1 were not significantly elevated during regrowth. Thus, the
CCR5-CCL5 chemokine signaling axis is a potential mechanism
for MSC recruitment during prostate regrowth.
GFP-tagged MSCs were injected into mice to identify MSC
recruitment to the prostate. We used intact or castrated host mice
that were given exogenous testosterone for zero or three days,
correlating with the highest level of BMDC recruitment. We then
monitored MSC recruitment by GFP immunohistochemical
staining and found a pattern similar to that seen with BMDC
recruitment (Figure 4). The GFP-MSCs were recruited to intact
prostates at low levels (mean=7.25 cells per field of view).
Castrated mice had elevated MSC recruitment to the epithelial
compartment of the prostate (mean=25.75). Further elevation in
MSC recruitment was observed following three days of testoster-
one supplementation (mean=38.55). Importantly, examination of
other tissues of the same mice (liver, intestine) revealed no
detectible GFP-MSCs. Thus, the bone marrow derived MSC
population could selectively incorporate into the prostate during
Figure 2. BMDCs incorporated into the prostate during regrowth. Immunofluorescence staining localized GFP-BMDCs (green) with prostate-
specific markers (red). DAPI stained the nuclei (blue). A) Androgen receptor, B) p63, and C) cytokeratin 8 were expressed in recruited GFP-BMDCs. D)
GFP-BMDCs had minimal co-expression of the hematopoietic marker, CD45.
doi:10.1371/journal.pone.0012920.g002
Figure 3. MSCs were functionally verified. Functional assays verified tri-lineage differentiation potential of mesenchymal stem cells after
culturing for three weeks. Adipogenic differentiation was verified by staining with Oil Red-O; lipid droplets stained a red color. Chondrogenic
differentiation was verified by staining with alcian blue; matrix sulfated proteoglycans stained a turquoise blue color. Osteogenic differentiation was
verified by alkaline phosphatase staining; osteogenic cells stained a deep fuschia color.
doi:10.1371/journal.pone.0012920.g003
MSCs Target Prostate Regrowth
PLoS ONE | www.plosone.org 4 September 2010 | Volume 5 | Issue 9 | e12920regrowth. The fusion or transdifferentiation of MSCs is reported
in other model systems [26,27].
We tested the potential of using MSC cell fusion or
differentiation as a mechanism for targeting genetic material to
CRPC. We used chicken b-actin-GFP mice as hosts for MSCs
obtained from FSP1-Cre/Rosa26 mice. The development of
FSP1-Cre/Rosa26 mice enabled MSC lineage tracing through the
expression of b-galactosidase. Prostates of castrated mice were
visualized by confocal fluorescent microscopy following three days
of testosterone supplementation. We identified prostate epithelial
cells that co-expressed GFP with b-galactosidase as an indication
of fusion of the MSCs to the prostate epithelia (Figure 5). We
calculated the percentage of recruited MSCs shown to undergo
fusion at 48.9% (n=5 mice, 20 fields of view).
To further explore the role of MSCs in CRPC growth and their
potential for targeted therapy, we used the C4-2B human CRPC
cell line, well characterized to grow as xenografts in castrated host
mice [28]. Based on the documented importance of Wnt signaling
in CRPC [29,30], we stably transduced C4-2B cells with a TCF/
LEF responsive luciferase reporter lentivirus. This allowed us to
monitor canonical Wnt activity within the tumor epithelia. We
then transduced MSCs with either GFP adenovirus as a control or
SFRP2 adenovirus. We hypothesized that MSCs could home to
C4-2B tumors and secrete SFRP2 to inhibit tumor progression. To
generate the CRPC model, we orthotopically grafted C4-2B cells
into each of the anterior lobes of SCID mouse prostates. The
experimental timeline is summarized (Figure 6A). After ten days of
tumor growth, the host mice were castrated. Serum testing
indicated continued expression of PSA in C4-2B tumor bearing
mice following castration, as expected. To test the efficacy of
MSCs as a therapeutic tool for CRPC, we subsequently injected
host mice with vehicle, GFP-transduced MSCs, or SFRP2-
transduced MSCs and harvested the tumors five days after
castration.
After harvesting the C4-2B tumors, we measured TCF/LEF-
luciferase activity, proliferation, and apoptosis. Analysis of
luciferase expression from the lysed tumors revealed that mice
given GFP-MSCs showed a 24-fold increase of canonical Wnt
activity within the C4-2B tumor epithelia compared to controls
(Figure 6B). Tumors from mice injected with SFRP2-MSCs had
no difference in canonical Wnt activity compared to controls. This
surprising finding suggested that five days following castration,
wild type MSCs contribute to CRPC by enhancing Wnt signaling
activity. Manipulating the MSCs to secrete SFRP2 caused reduced
proliferation and elevated apoptosis associated with increased
necrosis within the tumors.
H&E staining indicated focal areas of necrosis in control C4-2B
tumors and in mice given GFP-MSCs (Figure 6C, D). The C4-2B
Figure 4. MSCs were recruited to the prostate during regrowth. GFP-MSCs (brown) were recruited to the prostates of mice at the indicated
time points during regrowth. MSC recruitment was focal, and quantitation was performed for selected fields of view with detectable MSCs. Oneway
Welch ANOVA allowing for unequal variances was used to test differences between the experimental groups and the intact group (n=20), followed
by a two-sample t tests with unequal variances. The omnibus of statistic from the ANOVA was 89.0 (p,0.0001). Two-sample t tests with unequal
variances tests showed a statistically significant increase between intact (mean =7.25 cells per field of view) and castrated (mean =25.75 cells,
probability ,0.0001) and castrated +3dT (mean =38.55 cells, probability ,0.0001).
doi:10.1371/journal.pone.0012920.g004
Figure 5. MSCs fused to the prostate during regrowth. b-galactosidase-expressing MSCs were injected into castrated GFP mice supplemented
with exogenous testosterone for three days. Confocal microscopy showed colocalization of b-galactosidase-expressing MSCs (red) with GFP prostate
ducts (green). Nuclei were stained with TO-PRO-3 (blue). Merged color panel illustrates colocalization of MSCs (red) with prostate epithelia (green),
indicated by yellow. Fusion occurred in 48.9% of recruited MSCs.
doi:10.1371/journal.pone.0012920.g005
MSCs Target Prostate Regrowth
PLoS ONE | www.plosone.org 5 September 2010 | Volume 5 | Issue 9 | e12920tumors in mice given SFRP2-MSCs had comparatively greater
areas of necrosis (Figure 6E). Tumor proliferation was analyzed by
immunohistochemical localization of phosphorylated histone-H3,
indicating cells undergoing mitotic division (Figure 6F-H). The
mitotic rates of control and GFP-MSC-associated tumors were
similar (Figure 6D, E). However, the mitotic rate in SFRP2-MSC-
associated tumors was significantly lower than in control tumors (p
value =0.0069, Figure 6F). We next analyzed apoptosis in these
tumors using TUNEL staining (Figure 6G-I). Control and GFP-
MSC-associated tumors had similar apoptotic cell numbers
(Figure 6G, H). However, SFRP2-MSC tumors had a significant
increase in apoptotic cells (p value =0.0066, Figure 6I). Together,
we found MSC recruitment to CRPC xenografts to support Wnt
signaling and the targeted antagonism of Wnt signaling by MSCs
can potentiate reduced tumor growth.
Discussion
Recruited BMDCs enhanced tumor progression through
paracrine Wnt signaling. We found that the highest levels of
BMDC recruitment occurred during prostate regrowth at three
days. Interestingly, previous reports indicated that the highest level
Figure 6. GFP-MSCs recruited to human CRPC xenografts enhanced Wnt signaling. A) The experimental setup is summarized in the
timeline. C4-2B cells were orthotopically injected into the prostates of SCID mice. After 10 days the mice were castrated and MSCs were given
24 hours following castration. The tumors were harvested five days following castration. B) TOP-Flash luciferase activity was measured in C4-2B
tumors. GFP-MSCs increased Wnt activity within the tumors by 24-fold compared to control uninjected tumors. SFRP2-MSCs suppressed Wnt activity
comparable to basal levels. C4-2B tumors were sectioned and stained for histological analysis five days following castration. C4-2B tumors had
necrosis in the C) absence of MSCs, D) GFP-MSCs, and E) the greatest in SFRP2-MSC injected mice. F) Basal levels of phosphorylated histone-H3 were
observed in tumors without MSCs and G) GFP-MSCs. H) Proliferation was significantly decreased in tumors with SFRP2-MSCs (p value =0.0069). I)
Basal levels of TUNEL-positive apoptosis were found in tumors without MSCs and J) GFP-MSCs. K) A significant increase in apoptosis was seen in
tumors with SFRP2-MSCs (p value =0.0066). Areas of necrosis were avoided in quantitating TUNEL positive cells.
doi:10.1371/journal.pone.0012920.g006
MSCs Target Prostate Regrowth
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testosterone re-introduction, suggesting that peak tissue remodel-
ing corresponds to greatest recruitment of BMDCs. This was to be
expected, since BMDCs include inflammatory responsive cells
such as leukocytes and macrophages, associated with clearing dead
cells. However, this study demonstrated that a sub-population of
BMDCs, MSCs, are recruited to potentiate re-growth. MSCs may
provide growth factors that aid cancer progression in this complex
signaling microenvironment (Figure 7). We were able to employ
MSCs to target regrowing prostate tissue and deliver SFRP2,
antagonizing Wnt-mediated tumor progression.
Based on the microarray analysis of the Tgfbr2
fspKO CRPC
mouse model, (Table 1) and xenografted human CRPC C4-2B
cells (Figure 6) it is likely that MSCs were recruited during
regrowth through the CCL5-CCR5 axis. To broaden our
understanding of mechanisms of CRPC, signaling pathway
alterations based on LCM-microarray from Tgfbr2
fspKO com-
pared to Tgfbr2
floxE2/floxE2 mouse stroma were analyzed. Inter-
estingly, many more chemokines were upregulated than down-
regulated in the Tgfbr2
fspKO prostate stroma. Of particular
interest, CCL5 had a 70-fold increase in Tgfbr2
fspKO stroma
(Table 1). CCL5 is known to be upregulated in prostate cancer
[31]. It has also been shown to be a potent recruiter of BMDCs,
including MSCs [32]. A significant alteration of chemokine
signaling within the tumor microenvironment was likely to result
in BMDC recruitment. The multiple co-morbidities of the
Tgfbr2
fspKO mice [3,5,6,33] prevented us from generating
chimeric mice using these as the host to track BMDC recruitment
to the prostate. Therefore, we looked at recruitment during
prostate regrowth in wild type mice as a way to understand this
aspect of CRPC.
We demonstrated how the recruited mesenchymal stem cells
home to and contribute to CRPC by enhancing Wnt signaling
within the tumor epithelia. Using MSCs as a delivery tool for
secreted frizzled related protein 2 suppressed the enhanced Wnt
signaling in the tumor epithelia to effectively increase apoptosis.
MSCs may be used to deliver other gene therapeutics to enable
CRPC regression. Using MSCs as a targeted delivery tool is also a
way to avoid the toxicity associated with other less specific
therapies. When targeting signaling pathways that have systemic
effects, such as Wnt, it is especially necessary to avoid widespread
repercussions.
We showed that MSCs incorporate themselves into the prostate
epithelia through fusion. It is likely that the total number of
recruited MSCs is over-estimated due to the experimental
conditions of administering one million MSCs. However, the
percentage of recruited MSCs observed to undergo fusion (48.9%),
is likely similar to endogenous fusion events, respectively. Other
studies have demonstrated how hematopoietic stem cells incorpo-
rate into the gastrointestinal epithelia through fusion during
inflammation and proliferation [34]. Prostate injury from vaccinia
virus infection can cause inflammation and glandular disruption,
resulting in BMDC reconstitution of 4% of the prostate epithelium
[35]. Other studies have shown BMDCs recruited to and then
incorporate into resulting epithelial tissues found in lung, liver,
skin, heart, and the gastrointestinal tract [36,37,38]. Cancer
recurrence is linked to cell fusion [39]. CRPC cells have properties
including increased drug resistance, increased resistance to
apoptosis, and enhanced malignancy that are known to result
from cells that have undergone cell fusion [39]. We did not rule
out the possibility of transdifferentiation into prostate epithelial
lineages. The chicken b-actin-GFP mice used in the fusion
experiment had focal expression of GFP in the prostate.
Therefore, the presence of b-galactosidase expressing MSCs in
the absence of GFP could indicate transdifferentiation of the
MSCs that incorporated into the prostate epithelia or fusion that
we could not visualize due to the lack of GFP expression in those
prostate epithelial cells. It is possible that both fusion and
transdifferentiation are mechanisms of MSC incorporation into
the prostate epithelia. Others have suggested that cancer stem cells
may arise from the fusion of BMDCs with cancer cells, giving rise
to cells more capable of evading immune control. While our study
could not look at every possibility, we demonstrated the
involvement of MSCs in the cancer microenvironment and the
possibility of using MSCs to deliver therapeutic genes to control
prostate cancer.
In the C4-2B xenograft studies, the recruitment of GFP-MSCs
enhanced Wnt activity within the tumors. However, there was
little effect on proliferation, apoptosis, or tumor size in C4-2B
xenografts in the presence or absence of GFP-MSC recruitment.
This may be because C4-2B cells express high levels of Wnt
ligands endogenously, masking the effects of Wnt expression by the
GFP-MSCs. This led us to hypothesize that MSCs may have a
greater influence on androgen dependent tumors with lower
amounts of Wnt that would be more sensitive to additional Wnt
produced in the prostate microenvironment. By understanding
how these MSC act upon cancer cells and contribute to the tumor
microenvironment, we could learn to manipulate these cells to
counteract their cancer promoting effects. We had some success in
suppressing C4-2B tumor proliferation and promoting apoptosis
with MSC-targeted SFRP2 expression. However, we did not
observe a significant reduction in tumor size. Targeting Wnt
signaling is just one route for suppressing cancer progression. An
Figure 7. MSCs contribute to CRPC. This diagram represents a
transformed prostate gland. Rounded turquoise rectangles indicate
epithelial cells with an irregular nuclear shape and the larger pink half
moon shapes represent the stromal compartment. The stroma
surrounds the ducts, and is invaded by the transformed epithelia. The
recruited endogenous-MSCs (red) contribute to Wnt signaling in CRPC.
Whereas, the recruited therapeutic-MSCs that express SFRP-2 (blue)
antagonize Wnt signaling in CRPC. Rounded red rectangles indicate
epithelial cells that have fused with recruited MSCs.
doi:10.1371/journal.pone.0012920.g007
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effective in this late stage of cancer progression to provide a lasting
effect on tumor size.
Collectively, these studies demonstrated that BMDCs are
involved in prostate regrowth and cancer progression. BMDCs,
and in particular MSCs, are recruited to tissues undergoing active
remodeling, including the cancer microenvironment. Given the
innate cancer-homing capabilities of MSCs, it may be possible to
use these cells to treat CRPC with therapeutic gene delivery.
Materials and Methods
Ethics Statement
The Vanderbilt Institutional Animal Care and Use Committee
approved all animal procedures (M/06/236).
Mice and Fetal Liver Transplants
Harlan C57BL/6 wild type mice were purchased (Harlan,
Indianapolis, IN). Chicken b-actin-GFP mice were purchased from
Jackson Laboratories and GFP expression was confirmed by
visualizationwithUV light.Tgfbr2
floxE2/floxE2[40]and Tgfbr2
fspKO
[3] mice with C57BL/6 background were generated as previously
described. Fsp-Cre+/Rosa26 mice enabled b-gal visualization of
cells after Cre-mediated recombination. All mice were genotyped
from ear punch biopsies as previously reported [40,41,42]. Fetal
liver transplants (FLTs) were performed as previously described
[43]. Briefly, E14 embryonic livers from GFP+ mice were lysed into
single cell suspensions for tailvein injections (2610
6 cells per mouse)
into lethally irradiated recipient male mice using a [
137Cs] gamma
source by giving a split dose of 1200 rads. The host mice were either
intact or castrated four weeks prior to the FLT procedure. To
minimize infection from a diminished immune system, mice were
kept on acidified antibiotic water for two weeks before and four
weeks after FLTs. Four weeks after FLTs, prostate regrowth was
monitored following subcutaneous implantations of testosterone
pellets.
Laser Capture Microdissection and RNA Isolation for
Microarray
Tgfbr2
floxE2/floxE2 and Tgfbr2
fspKO mouse prostates were dis-
sected and frozen in liquid nitrogen. Cryosections of the prostates
were used for laser capture microdissection of the stroma. RNA was
isolated using a mMACS mRNA isolation kit following the
manufacturer’s protocol (Miltenyi Biotec, Auburn, CA). Samples
were lysed in SuperAmp Lysis Buffer and sent for processing and
microarray analysis. Miltenyi Biotec amplified the RNA, produced
cDNA, and hybridized to Agilent whole genome oligo microarrays.
Fluorescent signals were detected and Agilent Feature Extraction
Software was used to read and process the microarray image files.
Gene lists were given as normalized Cy5/Cy3-fold changes. The
microarray data sets were submitted to the NCBI GEO database
accession number GSE22130. The selected table included fold
change values averaged from three data sets per genotype, each
having a fold change .2 and p-value ,0.01.
MSC Generation and Verification
Bone marrow derived mesenchymal stem cells were derived as
previously described [25,44,45]. Bone marrow was flushed from
mice femurs and tibias aged eight to twelve weeks. Red blood cells
were lysed and the remaining bone marrow cells plated in MSC
expansion media [25,45]. Adherent MSCs were selected and
expanded for ten days. Cells were then trypsinized and plated for
differentiation assays or used for tail vein injections into host mice
(10
6 cells injected per mouse).
Osteogenic differentiation of MSCs was performed as previ-
ously described [46]. MSCs were switched to osteogenic inducing
media for three weeks, consisting of high glucose DMEM
supplemented with 10% fetal bovine serum, 100 mM dexameth-
asone, 0.1 mM ascorbic acid, and 10 nM b-glycerophosphate.
Osteogenic differentiation was confirmed by alkaline phosphatase
staining according to the manufacturer’s directions (Sigma-
Aldrich, St. Louis, MO).
Chondrogenic differentiation of MSCs was performed as
previously described [46]. MSCs were switched to chondrogenic
inducing media for three weeks, consisting of high glucose DMEM
supplemented with 10% fetal bovine serum, 100 mM dexameth-
asone, and 0.1 mg/mL TGF-b. Chondrogenic differentiation was
confirmed by alcian blue (pH 1.0) staining. Cells were fixed for
20 min at RT in 10% formalin, washed with PBS, stained with
alcian blue for 20 min and washed with PBS.
Adipogenic differentiation of MSCs was performed as previ-
ously described [46]. MSCs were switched to adipogenic inducing
media for three weeks, consisting of high glucose DMEM
supplemented with 10% fetal bovine serum, 10 mM dexametha-
sone, 10 mg/mL insulin, and 100 mg/mL IBMX. Adipogenic
differentiation was confirmed by Oil Red-O staining.
Immunohistochemistry and Immunofluorescence
Tissues were fixed with 4% paraformaldehyde or 10% formalin,
embedded in paraffin, and sectioned for histological analysis. GFP
(1:1000, Santa Cruz, CA) and phosphorylated-histone H3 (1:500,
Upstate, Temecula, CA) immunohistochemistry was performed
using antigen retrieval with antigen unmasking solution (Vector
Laboratories, Burlngame, CA) diluted 1:100. Following primary
antibody incubation overnight, Dako Cytomation Universal or
Rabbit kits were used for the secondary antibody and development
with DAB. TUNEL staining was performed using the ApopTag
Peroxidase In Situ Apoptosis Detection Kit (Millipore, Temecula,
CA) as directed. Immunohistochemical staining was quantitated
by taking a ratio of positively stained cells per field (4006)
MetaMorph 7.6 software was used to help quantitate the
immunohistochemical staining. Statistical significance was deter-
mined by two tailed Student’s t test.
Tissues were fixed with 4% paraformaldehyde or 10% formalin,
embedded in paraffin, and sectioned for histological analysis.
Antigen retrieval with antigen unmasking solution (Vector
Laboratories, Burlngame, CA) diluted 1:100 was performed.
Staining was performed for GFP (1:100, Santa Cruz, CA), b-
galactosidase (1:750, Abcam, Cambridge MA), Cytokeratin 8
(1:100, University of Iowa Hybridoma Bank, Iowa City, IA), p63
(1:50, Calbiochem, Gibbstown, NJ), androgen receptor (1:50,
Santa Cruz, CA), and CD45 (1:50, BD Biosciences, San Jos, CA).
Secondary anti-mouse or anti-rabbit Alexa Fluor 594 (red), Alexa
Fluor 546 (orange-red) or Alexa Fluor 488 (green) were used as
indicated (1:500, Invitrogen, Carlsbad, CA). TO-PRO-3 iodide
was used for confocal nuclear counterstaining (Invitrogen, Eugene,
OR). DAPI mounting media was used for widefield immunoflu-
orescence staining (Vector Laboratories, Burlngame, CA). Wide-
field images were taken on a Nikon epifluorescence microscope
and a Leica DM IRB inverted microscope. Z-series slices were
taken on a Zeiss LSM510 META inverted confocal microscope.
Statistical Analysis
Oneway ANOVA was performed to test differences between the
experimental and control groups, followed by Dunnett’s post-hoc
tests when the variances were equal. When variances were
unequal, oneway Welch ANOVA allowing for unequal variances
was used to test differences between the experimental groups and
MSCs Target Prostate Regrowth
PLoS ONE | www.plosone.org 8 September 2010 | Volume 5 | Issue 9 | e12920the intact group, followed by a two-sample t tests with unequal
variances.
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